Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Incyte (NASDAQ: INCY) and the best and worst performers in the immuno-oncology industry.
Over the next few years, immuno-oncology companies, which harness the immune system to fight illnesses such as cancer, faces strong tailwinds from advancements in precision medicine (including the use of AI to improve hit rates) and growing demand for treatments targeting rare diseases. However, headwinds such as rising scrutiny over drug pricing, regulatory unknowns, and competition from larger, more resourced pharmaceutical companies could weigh on growth.
The 4 immuno-oncology stocks we track reported a strong Q4. As a group, revenues beat analysts’ consensus estimates by 3.5%.
Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 18.2% since the latest earnings results.
Weakest Q4: Incyte (NASDAQ: INCY)
Founded in 1991 and evolving from a genomics research firm to a commercial-stage drug developer, Incyte (NASDAQ: INCY) is a biopharmaceutical company that discovers, develops, and commercializes proprietary therapeutics for cancer and inflammatory diseases.
Incyte reported revenues of $1.18 billion, up 16.3% year on year. This print exceeded analysts’ expectations by 3%. Despite the top-line beat, it was still a slower quarter for the company with a significant miss of analysts’ EPS estimates.
"2024 was an important year for Incyte, with a 15% increase in total revenues, driven by strong growth from both Jakafi and Opzelura, as well as significant progress across our R&D pipeline," said Hervé Hoppenot, Chief Executive Officer, Incyte.
The stock is down 20.5% since reporting and currently trades at $59.
Read our full report on Incyte here, it’s free.
Best Q4: Natera (NASDAQ: NTRA)
Founded in 2003 as Gene Security Network before rebranding in 2012, Natera (NASDAQ: NTRA) develops and commercializes genetic tests for prenatal screening, cancer detection, and organ transplant monitoring using its proprietary cell-free DNA technology.
Natera reported revenues of $476.1 million, up 53% year on year, outperforming analysts’ expectations by 8.6%. The business had a stunning quarter with a solid beat of analysts’ EPS estimates and full-year revenue guidance exceeding analysts’ expectations.
Natera pulled off the biggest analyst estimates beat, fastest revenue growth, and highest full-year guidance raise among its peers. Although it had a fine quarter compared to its peers, the market seems unhappy with the results as the stock is down 18.9% since reporting. It currently trades at $127.08.
Is now the time to buy Natera? Access our full analysis of the earnings results here, it’s free.
Regeneron (NASDAQ: REGN)
Founded by scientists who wanted to build a company where science could thrive, Regeneron Pharmaceuticals (NASDAQ: REGN) develops and commercializes medicines for serious diseases, with key products treating eye conditions, allergic diseases, cancer, and other disorders.
Regeneron reported revenues of $3.79 billion, up 10.3% year on year, exceeding analysts’ expectations by 1%. It was a decent quarter as it also locked in a decent beat of analysts’ EPS estimates.
The stock is down 14.6% since the results and currently trades at $568.90.
Read our full analysis of Regeneron’s results here.
Exact Sciences (NASDAQ: EXAS)
With a mission to detect cancer earlier when it's more treatable, Exact Sciences (NASDAQ: EXAS) develops and markets cancer screening and diagnostic tests, including its flagship Cologuard stool-based colorectal cancer screening test.
Exact Sciences reported revenues of $713.4 million, up 10.3% year on year. This number beat analysts’ expectations by 1.6%. It was a strong quarter as it also put up an impressive beat of analysts’ constant currency revenue estimates and a solid beat of analysts’ EPS estimates.
Exact Sciences had the slowest revenue growth and weakest full-year guidance update among its peers. The stock is down 18.7% since reporting and currently trades at $41.
Read our full, actionable report on Exact Sciences here, it’s free.
Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Quality Compounder Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.
Join Paid Stock Investor Research
Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here.
